Show simple item record

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors.

dc.contributor.authorPacey, S
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorGarcia-Corbacho, J
dc.contributor.authorLipplaa, A
dc.contributor.authorFusi, Alberto
dc.contributor.authorKumar, S
dc.contributor.authorHategan, M
dc.contributor.authorDerham, J
dc.contributor.authorLaviste, Glenda
dc.contributor.authorHalford, S
dc.contributor.authorFoxton, C
dc.contributor.authorMcLeod, R
dc.contributor.authorWan, S
dc.contributor.authorTalbot, D
dc.date.accessioned2017-04-23T20:05:04Z
dc.date.available2017-04-23T20:05:04Z
dc.date.issued2016-10-01
dc.identifier.citationA phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors. 2016, 27(suppl_6):1082P Annals of Oncologyen
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.doi10.1093/annonc/mdw383.61
dc.identifier.urihttp://hdl.handle.net/10541/620273
dc.language.isoenen
dc.relation.urlhttps://academic.oup.com/annonc/article/2800154/Aen
dc.rightsArchived with thanks to Annals of Oncologyen
dc.titleA phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentOncology, Addenbrooke’s Hospital, University of Cambridge, Cambridgeen
dc.identifier.journalAnnals of Oncologyen


This item appears in the following Collection(s)

Show simple item record